Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Eur J Haematol Retrieve available abstracts of 151 articles: HTML format

Single Articles

June 2024
1. SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
   Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
   Eur J Haematol. 2024;112:944-956.
   PubMed     Abstract available
   
   
   
2. GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
   Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
   Eur J Haematol. 2024;112:927-937.
   PubMed     Abstract available
   
   
   
3. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
   Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
   Eur J Haematol. 2024;112:984-987.
   PubMed     Abstract available
   
   
   May 2024
4. TAGHILOO S, Asgarian-Omran H
   Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
   Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
   PubMed     Abstract available
   
   
   
5. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
   Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
   Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
   PubMed     Abstract available
   
   
   April 2024
6. AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
   Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
   Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
   PubMed     Abstract available
   
   
   
7. MARRA JD, Galli E, Giammarco S, Metafuni E, et al
   CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
   Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
   PubMed     Abstract available
   
   
   
8. MIKLOS E, Oliver TP, Adam K, Eva K, et al
   Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
   Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
   PubMed     Abstract available
   
   
   
9. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
   Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
   Eur J Haematol. 2024;112:601-610.
   PubMed     Abstract available
   
   
   
10. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
    Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
    Eur J Haematol. 2024;112:627-632.
    PubMed     Abstract available
    
    
    
11. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
    Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Eur J Haematol. 2024;112:530-537.
    PubMed     Abstract available
    
    
    
12. ISHIKAWA C, Mori N
    Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
    PubMed     Abstract available
    
    
    March 2024
13. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
    Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
    PubMed     Abstract available
    
    
    
14. ZHANG X, Zhang K, Zhang J, Chang W, et al
    DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
    Eur J Haematol. 2024;112:439-449.
    PubMed     Abstract available
    
    
    
15. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    PubMed     Abstract available
    
    
    February 2024
16. GAO J, Santana-Santos L, Fu L, Alvey E, et al
    Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Eur J Haematol. 2024 Feb 22. doi: 10.1111/ejh.14192.
    PubMed     Abstract available
    
    
    
17. SUN Y, Zhu G, Zhong H
    Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Eur J Haematol. 2024 Feb 11. doi: 10.1111/ejh.14187.
    PubMed     Abstract available
    
    
    
18. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
    Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
    PubMed     Abstract available
    
    
    
19. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
    Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
    Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
    PubMed     Abstract available
    
    
    
20. SEVOYAN A, Mekinian A, Chermat F, Ades L, et al
    MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
    Eur J Haematol. 2024;112:296-300.
    PubMed     Abstract available
    
    
    January 2024
21. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
    Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
    PubMed     Abstract available
    
    
    
22. PODGORICA M, Drivet E, Viken JK, Richman A, et al
    Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
    Eur J Haematol. 2024 Jan 8. doi: 10.1111/ejh.14164.
    PubMed     Abstract available
    
    
    
23. MOYEN TB, Tomaz V, Campregher PV
    Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14158.
    PubMed     Abstract available
    
    
    
24. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    PubMed     Abstract available
    
    
    
25. WANG XY, Bian MR, Lin GQ, Yu L, et al
    Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Eur J Haematol. 2024;112:83-93.
    PubMed     Abstract available
    
    
    
26. JI Q, Wu X, Zhang Y, Zeng L, et al
    Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
    Eur J Haematol. 2024;112:75-82.
    PubMed     Abstract available
    
    
    
27. KHAN AN, Asija S, Pendhari J, Purwar R, et al
    CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Eur J Haematol. 2024;112:6-18.
    PubMed     Abstract available
    
    
    December 2023
28. TAMEFUSA K, Ochi M, Ishida H, Shiwaku T, et al
    Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14162.
    PubMed     Abstract available
    
    
    
29. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    PubMed     Abstract available
    
    
    
30. NEUMANN MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, et al
    A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
    Eur J Haematol. 2023 Dec 17. doi: 10.1111/ejh.14153.
    PubMed     Abstract available
    
    
    
31. COSTA A, Carmosino I, Scalzulli E, Minotti C, et al
    Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
    Eur J Haematol. 2023 Dec 14. doi: 10.1111/ejh.14155.
    PubMed    
    
    
    
32. LAGANA A, Pepe S, Scalzulli E, Carmosino I, et al
    One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
    Eur J Haematol. 2023;111:970-972.
    PubMed    
    
    
    November 2023
33. NEVEJAN L, Labarque V, Boeckx N
    Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
    Eur J Haematol. 2023 Nov 20. doi: 10.1111/ejh.14137.
    PubMed     Abstract available
    
    
    
34. LEE BJ, Griffin SP, Doh J, Chan A, et al
    HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Nov 6. doi: 10.1111/ejh.14125.
    PubMed     Abstract available
    
    
    October 2023
35. SEGHATOL-ESLAMI VC, Cook EW 3rd, Sharafeldin N, Wolfson J, et al
    Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support.
    Eur J Haematol. 2023 Oct 5. doi: 10.1111/ejh.14112.
    PubMed     Abstract available
    
    
    
36. KRISTENSEN DT, Brondum RF, Orskov AD, Marcher CW, et al
    Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
    Eur J Haematol. 2023;111:573-582.
    PubMed     Abstract available
    
    
    
37. MIYAJIMA T, Onozawa M, Yoshida S, Miyashita N, et al
    Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Eur J Haematol. 2023;111:620-627.
    PubMed     Abstract available
    
    
    
38. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    PubMed     Abstract available
    
    
    September 2023
39. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    PubMed     Abstract available
    
    
    
40. KOCKEROLS C, Valk PJM, Blijlevens NMA, Cornelissen JJ, et al
    BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
    Eur J Haematol. 2023 Sep 20. doi: 10.1111/ejh.14107.
    PubMed     Abstract available
    
    
    
41. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    PubMed     Abstract available
    
    
    
42. ZARLING LC, Stevenson PA, Soma LA, Martino CH, et al
    Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 5. doi: 10.1111/ejh.14089.
    PubMed     Abstract available
    
    
    August 2023
43. SLJIVIC I, Fulford A, Ho J, Lazo-Langner A, et al
    Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
    Eur J Haematol. 2023 Aug 28. doi: 10.1111/ejh.14094.
    PubMed     Abstract available
    
    
    
44. CANALE FA, Pitea M, Alati C, Porto G, et al
    Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation.
    Eur J Haematol. 2023 Aug 21. doi: 10.1111/ejh.14087.
    PubMed     Abstract available
    
    
    
45. ANDERSSON ML, Johansson H, Osterborg A, Mansson-Broberg A, et al
    Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
    Eur J Haematol. 2023 Aug 10. doi: 10.1111/ejh.14072.
    PubMed     Abstract available
    
    
    
46. MILOJKOVIC D, Lyon AR, Mehta P, Dimitriadou E, et al
    Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management.
    Eur J Haematol. 2023;111:201-210.
    PubMed     Abstract available
    
    
    
47. HEFTDAL LD, Hamm SR, Perez-Alos L, Madsen JR, et al
    Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
    Eur J Haematol. 2023;111:229-239.
    PubMed     Abstract available
    
    
    July 2023
48. LARFORS G, Andersson P, Jesson G, Liljebris C, et al
    Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
    Eur J Haematol. 2023 Jul 28. doi: 10.1111/ejh.14059.
    PubMed     Abstract available
    
    
    
49. MATTSSON A, Sylvan SE, Axelsson P, Ellin F, et al
    Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14065.
    PubMed     Abstract available
    
    
    
50. GIUDICE V, Serio B, Errichiello S, Ferrara I, et al
    Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14069.
    PubMed     Abstract available
    
    
    
51. ALFARO MOYA T, Mattsson J, Remberger M, Lipton JH, et al
    Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission.
    Eur J Haematol. 2023 Jul 18. doi: 10.1111/ejh.14041.
    PubMed     Abstract available
    
    
    
52. FETSCH V, Zeiser R
    Chimeric antigen receptor T cells for acute myeloid leukemia.
    Eur J Haematol. 2023 Jul 16. doi: 10.1111/ejh.14047.
    PubMed     Abstract available
    
    
    
53. KOO M, Song IC, Kim J, Kwon GC, et al
    Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia.
    Eur J Haematol. 2023 Jul 12. doi: 10.1111/ejh.14044.
    PubMed     Abstract available
    
    
    
54. BADAL S, Taheri M, Jiang P, Oh K, et al
    Rare presence of Charcot-Leyden crystals in acute myeloid leukemia.
    Eur J Haematol. 2023 Jul 7. doi: 10.1111/ejh.14037.
    PubMed    
    
    
    
55. ZHOU Q, Zhao D, Zarif M, Yeung YWT, et al
    Impact of secondary-type mutations in NPM1 mutated AML.
    Eur J Haematol. 2023;111:165-168.
    PubMed    
    
    
    
56. REDONDO S, Garcia-Cadenas I, Vila A, Esquirol A, et al
    Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
    Eur J Haematol. 2023;111:146-153.
    PubMed     Abstract available
    
    
    June 2023
57. TORRENT A, Morgades M, Garcia-Calduch O, de Llano MPQ, et al
    Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
    Eur J Haematol. 2023 Jun 28. doi: 10.1111/ejh.14031.
    PubMed     Abstract available
    
    
    
58. ZHOU J, Zhou Y, Yuan S, Li Y, et al
    Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway.
    Eur J Haematol. 2023 Jun 21. doi: 10.1111/ejh.14006.
    PubMed     Abstract available
    
    
    
59. FRAIRIA C, Nicolino B, Secreto C, Messa E, et al
    Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy.
    Eur J Haematol. 2023;110:696-705.
    PubMed     Abstract available
    
    
    
60. FERRA COLL C, Morgades de la Fe M, Prieto Garcia L, Vaz CP, et al
    Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation.
    Eur J Haematol. 2023;110:659-668.
    PubMed     Abstract available
    
    
    
61. CHERNIAWSKY H, Friedmann J, Nicolson H, Dehghan N, et al
    VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
    Eur J Haematol. 2023;110:633-638.
    PubMed     Abstract available
    
    
    May 2023
62. CANAANI J, Frisch A, Pollyea DA, Schwartz M, et al
    Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Eur J Haematol. 2023 May 31. doi: 10.1111/ejh.14015.
    PubMed     Abstract available
    
    
    
63. TRAPE G, De Angelis G, Morucci M, Tarnani M, et al
    Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
    Eur J Haematol. 2023 May 26. doi: 10.1111/ejh.14012.
    PubMed     Abstract available
    
    
    April 2023
64. LEE BJ, Kongtim P, Doh J, Griffin SP, et al
    Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change.
    Eur J Haematol. 2023 Apr 22. doi: 10.1111/ejh.13980.
    PubMed     Abstract available
    
    
    
65. CHUNG C, Umoru G, Abboud K, Hobaugh E, et al
    Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
    Eur J Haematol. 2023 Apr 10. doi: 10.1111/ejh.13973.
    PubMed     Abstract available
    
    
    
66. CHRISTENSEN ME, Siersma V, Kriegbaum M, Lind BS, et al
    Monocytosis in primary care and risk of haematological malignancies.
    Eur J Haematol. 2023;110:362-370.
    PubMed     Abstract available
    
    
    March 2023
67. ITO Y, Ozawa H, Eto T, Miyamoto T, et al
    IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial.
    Eur J Haematol. 2023 Mar 29. doi: 10.1111/ejh.13972.
    PubMed     Abstract available
    
    
    
68. WEISCHENDORFF S, De Pietri S, Rathe M, Frandsen TL, et al
    Markers of neutrophil chemotaxis for identification of blood stream infections in children with acute lymphoblastic leukemia undergoing induction treatment.
    Eur J Haematol. 2023 Mar 23. doi: 10.1111/ejh.13962.
    PubMed     Abstract available
    
    
    
69. CRANE JC, Gordon MJ, Basen-Engquist K, Ferrajoli A, et al
    Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: results from the HEALTH4CLL pilot study.
    Eur J Haematol. 2023 Mar 22. doi: 10.1111/ejh.13958.
    PubMed     Abstract available
    
    
    February 2023
70. WANG Y, Li J, Xue TL, Tian S, et al
    Clinical, biological and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
    Eur J Haematol. 2023 Feb 22. doi: 10.1111/ejh.13948.
    PubMed     Abstract available
    
    
    
71. MOLICA S, Allsup D, Polliack A, Giannarelli D, et al
    The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis.
    Eur J Haematol. 2023 Feb 14. doi: 10.1111/ejh.13943.
    PubMed    
    
    
    
72. NAMPOOTHIRI RV, Tang K, Schuh A, Lam W, et al
    Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis.
    Eur J Haematol. 2023 Feb 2. doi: 10.1111/ejh.13940.
    PubMed     Abstract available
    
    
    
73. POURHASSAN H, Kim Y, Pullarkat V
    Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
    Eur J Haematol. 2023;110:213-216.
    PubMed     Abstract available
    
    
    
74. KLYUCHNIKOV E, Langebrake C, Badbaran A, Dadkhah A, et al
    Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
    Eur J Haematol. 2023;110:188-197.
    PubMed     Abstract available
    
    
    January 2023
75. ZHU G, Cai J, Zhong H
    TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
    Eur J Haematol. 2023 Jan 24. doi: 10.1111/ejh.13934.
    PubMed     Abstract available
    
    
    
76. TEY A, Schwarer J, Raffa R, Shi E, et al
    High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
    PubMed     Abstract available
    
    
    
77. JOHNSON AQ, Bannon SA, Farach LS, Hyde SM, et al
    Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy.
    Eur J Haematol. 2023;110:109-116.
    PubMed     Abstract available
    
    
    
78. BENJAMINI O, Gershon R, Bar-Haim E, Lustig Y, et al
    Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
    Eur J Haematol. 2023;110:99-108.
    PubMed     Abstract available
    
    
    
79. SEHGAL T, Sharma P
    Auer rods and faggot cells: A review of the history, significance and mimics of two morphological curiosities of enduring relevance.
    Eur J Haematol. 2023;110:14-23.
    PubMed     Abstract available
    
    
    
80. ABBOTT L, Claveau M, Tang K, Cameron J, et al
    The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review.
    Eur J Haematol. 2023;110:32-39.
    PubMed     Abstract available
    
    
    December 2022
81. CHEN Y, Shao X, Yang H, Ren L, et al
    Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia.
    Eur J Haematol. 2022 Dec 28. doi: 10.1111/ejh.13921.
    PubMed     Abstract available
    
    
    
82. KOSCHADE SE, Stratmann JA, Steffen B, Shaid S, et al
    Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy.
    Eur J Haematol. 2022 Dec 27. doi: 10.1111/ejh.13920.
    PubMed     Abstract available
    
    
    
83. BAI T, Liu N
    RNA-binding protein PUM2 promotes T-cell acute lymphoblastic leukemia via competitively binding to RBM5 3'UTR with miR-28-5p.
    Eur J Haematol. 2022 Dec 19. doi: 10.1111/ejh.13914.
    PubMed     Abstract available
    
    
    
84. RINGELSTEIN-HARLEV S, Fanadka M, Horowitz NA, Bettman NP, et al
    In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T-cell inhibitory properties, contributing to immunosuppression.
    Eur J Haematol. 2022 Dec 7. doi: 10.1111/ejh.13912.
    PubMed     Abstract available
    
    
    
85. TIRIBELLI M, Toffoletti E, Di Giusto S, Fanin R, et al
    Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
    Eur J Haematol. 2022 Dec 2. doi: 10.1111/ejh.13907.
    PubMed    
    
    
    
86. KANG SH, Kim HB, Choi JS
    Upregulation of microRNA-597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition.
    Eur J Haematol. 2022;109:680-685.
    PubMed     Abstract available
    
    
    November 2022
87. NEDUMANNIL R, Ritchie D, Bajel A, Ng AP, et al
    Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
    Eur J Haematol. 2022 Nov 2. doi: 10.1111/ejh.13890.
    PubMed     Abstract available
    
    
    
88. CHEN LY, Eyre TA
    Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.
    Eur J Haematol. 2022;109:590-592.
    PubMed     Abstract available
    
    
    
89. ELIZABETH S, Aidan K, David OB, Deirdre W, et al
    Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals.
    Eur J Haematol. 2022;109:441-446.
    PubMed     Abstract available
    
    
    October 2022
90. YOON JH, Kim HS, Min GJ, Park SS, et al
    Cytogenetic and molecular characteristics and outcomes of adult patients with early T-cell precursor acute lymphoblastic leukemia.
    Eur J Haematol. 2022 Oct 10. doi: 10.1111/ejh.13883.
    PubMed     Abstract available
    
    
    
91. BADAL S, Thapaliya P, Oh K
    Co-existence of Chronic lymphocytic leukemia and Chronic myeloid leukemia and underlying pathogenetic mechanisms.
    Eur J Haematol. 2022 Oct 7. doi: 10.1111/ejh.13879.
    PubMed    
    
    
    
92. GRAF I, Herndlhofer S, Kundi M, Greiner G, et al
    Incidence of Symptomatic Covid-19 Infections in Patients with Mastocytosis and Chronic Myeloid Leukemia: a Comparison with the General Austrian Population.
    Eur J Haematol. 2022 Oct 4. doi: 10.1111/ejh.13875.
    PubMed     Abstract available
    
    
    
93. MESSORI A
    Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.
    Eur J Haematol. 2022 Oct 3. doi: 10.1111/ejh.13873.
    PubMed     Abstract available
    
    
    September 2022
94. HEERING G, Sasson M, Dominissini D, Shimoni A, et al
    Contemporary evaluation of acute myeloid leukemia patients with long-term survival exceeding five years.
    Eur J Haematol. 2022 Sep 21. doi: 10.1111/ejh.13864.
    PubMed     Abstract available
    
    
    
95. DIAZ-SANTA J, Rodriguez-Romanos R, Coll R, Osca G, et al
    5'-nucleotidase, cytosolic ii genotype and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
    Eur J Haematol. 2022 Sep 5. doi: 10.1111/ejh.13862.
    PubMed     Abstract available
    
    
    
96. DANIEL A, Ghez D, Ravaiau C, Cavalieri D, et al
    Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
    Eur J Haematol. 2022 Sep 1. doi: 10.1111/ejh.13858.
    PubMed     Abstract available
    
    
    August 2022
97. EGNELL C, Narhinen H, Merker A, Jonsson OG, et al
    Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol.
    Eur J Haematol. 2022 Aug 25. doi: 10.1111/ejh.13848.
    PubMed     Abstract available
    
    
    July 2022
98. GIUDICE V, Serio B, Bertolini A, Mettivier L, et al
    Implementation of International Prognostic Index with Flow Cytometry Immunophenotyping for Better Risk Stratification of Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2022 Jul 24. doi: 10.1111/ejh.13833.
    PubMed     Abstract available
    
    
    June 2022
99. TRACY SI, Cao Q, Bachan B, Meredith M, et al
    Ph-like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation.
    Eur J Haematol. 2022 Jun 14. doi: 10.1111/ejh.13814.
    PubMed    
    
    
    
100. MURPHY P, Glavey S, Quinn J
     Intracranial haemorrhage in AML patients.
     Eur J Haematol. 2022;108:536.
     PubMed    
     
     
     
101. VU M, Degeling K, Thompson ER, Blombery P, et al
     Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
     Eur J Haematol. 2022;108:469-485.
     PubMed     Abstract available
     
     
     
102. KEEGAN A, Dennington PM, Dhondy N, Mulligan SP, et al
     Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
     Eur J Haematol. 2022;108:460-468.
     PubMed     Abstract available
     
     
     May 2022
103. KOLONEN A, Sinisalo M, Huhtala H, Rimpilainen J, et al
     Efficacy of conventional-dose cytarabine, idarubicin and thioguanine (IAT) versus intermediate-dose cytarabine and idarubicin (IdAraC-Ida) in the induction treatment of AML: long-term results of the prospective randomized nationwide AML-2003 study by
     Eur J Haematol. 2022 May 30. doi: 10.1111/ejh.13805.
     PubMed     Abstract available
     
     
     
104. ARCURI LJ, Lerner D, Tavares RCBDS
     Lower levels of cyclosporine between days 0 and +21 may reduce later relapses without increasing graft-versus-host disease in children and adolescents with acute lymphoblastic leukemia who undergo myeloablative TBI-based allogeneic hematopoietic cell
     Eur J Haematol. 2022 May 9. doi: 10.1111/ejh.13787.
     PubMed     Abstract available
     
     
     
105. STUBBINS RJ, Stamenkovic M, Roy C, Rodrigo J, et al
     Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort.
     Eur J Haematol. 2022;108:437-445.
     PubMed     Abstract available
     
     
     
106. VASUDEVAN NAMPOOTHIRI R, Pasic I, Law AD, Lam W, et al
     Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
     Eur J Haematol. 2022;108:430-436.
     PubMed     Abstract available
     
     
     April 2022
107. CLAUDIANI S, Janssen JJWM, Byrne J, Smith G, et al
     A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
     Eur J Haematol. 2022 Apr 11. doi: 10.1111/ejh.13775.
     PubMed     Abstract available
     
     
     
108. CHEE L, Ritchie D, Ludford-Menting M, Ripley J, et al
     Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS).
     Eur J Haematol. 2022;108:342-353.
     PubMed     Abstract available
     
     
     March 2022
109. GEISSLER K, Jager E, Barna A, Gurbisz M, et al
     Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
     Eur J Haematol. 2022 Mar 17. doi: 10.1111/ejh.13768.
     PubMed     Abstract available
     
     
     
110. ITO T, Sanford D, Tomuleasa C, Hsiao HH, et al
     Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
     Eur J Haematol. 2022 Mar 17. doi: 10.1111/ejh.13769.
     PubMed     Abstract available
     
     
     
111. MOLICA S, Giannarelli D, Montserrat E
     mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
     Eur J Haematol. 2022;108:264-267.
     PubMed    
     
     
     
112. WELLER JF, Mezger M, Seifert LL, Vogel W, et al
     Time-dependent analysis of adoptive immunotherapy following sequential FLAMSA-reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk myeloid neoplasia.
     Eur J Haematol. 2022;108:244-263.
     PubMed     Abstract available
     
     
     February 2022
113. PAPAYANNIDIS C, Nanni J, Cristiano G, Marconi G, et al
     Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
     Eur J Haematol. 2022 Feb 14. doi: 10.1111/ejh.13753.
     PubMed     Abstract available
     
     
     January 2022
114. HU R, Wei W, Mian A, Gonter-Aubin K, et al
     Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia at First Relapse.
     Eur J Haematol. 2022 Jan 18. doi: 10.1111/ejh.13744.
     PubMed     Abstract available
     
     
     
115. BRIEGHEL C, Galle V, Agius R, da Cunha-Bang C, et al
     Identifying patients with chronic lymphocytic leukemia without need of treatment (CLL-WONT): end of endless watch and wait?
     Eur J Haematol. 2022 Jan 14. doi: 10.1111/ejh.13743.
     PubMed     Abstract available
     
     
     
116. NOVITZKY-BASSO I, Remberger M, Chen C, Pasic I, et al
     Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
     Eur J Haematol. 2022;108:61-72.
     PubMed     Abstract available
     
     
     December 2021
117. CORNELISSEN LL, Kreuger AL, Caram-Deelder C, Huisman MV, et al
     Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia.
     Eur J Haematol. 2021 Dec 19. doi: 10.1111/ejh.13737.
     PubMed     Abstract available
     
     
     
118. NOSAKA K, Crawford B, Yi J, Kuan W, et al
     A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
     Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
     PubMed     Abstract available
     
     
     
119. FLYGT H, Soderlund S, Stentoft J, Richter J, et al
     Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
     Eur J Haematol. 2021;107:617-623.
     PubMed     Abstract available
     
     
     
120. SONG A, Altabbakh O, Sallman DA, Padron E, et al
     Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
     Eur J Haematol. 2021;107:609-616.
     PubMed     Abstract available
     
     
     November 2021
121. CUNNINGHAM I, Sosa SS, Hamele-Bena D
     A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
     Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
     PubMed     Abstract available
     
     
     
122. BUCHRITS S, Kozlovoski D, Gafter-Gvili A, Raanani P, et al
     Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 - Case Series and Review of the Literature.
     Eur J Haematol. 2021 Nov 8. doi: 10.1111/ejh.13725.
     PubMed     Abstract available
     
     
     
123. GUOLO F, Di Grazia C, Minetto P, Raiola AM, et al
     Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
     Eur J Haematol. 2021;107:573-582.
     PubMed     Abstract available
     
     
     October 2021
124. MORAWSKA M
     Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
     Eur J Haematol. 2021 Oct 30. doi: 10.1111/ejh.13722.
     PubMed     Abstract available
     
     
     
125. STEINGRIMSSON V, Lund SH, Dickman PW, Weibull CE, et al
     Survival, Causes of Death, and the Prognostic Role of Comorbidities in Chronic Lymphocytic Leukemia in the pre-ibrutinib era. A Population Based Study.
     Eur J Haematol. 2021 Oct 29. doi: 10.1111/ejh.13720.
     PubMed     Abstract available
     
     
     
126. KOSCHADE SE, Stratmann JA, Miesbach W, Steffen B, et al
     Intracranial hemorrhage in newly diagnosed non-promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy.
     Eur J Haematol. 2021 Oct 29. doi: 10.1111/ejh.13718.
     PubMed     Abstract available
     
     
     
127. TREMBLAY Z, Wong A, Otis AS, Pepin MA, et al
     Use of Midostaurin in Mixed Phenotype Acute Leukemia with FLT3 Mutation: A Case Series.
     Eur J Haematol. 2021 Oct 15. doi: 10.1111/ejh.13717.
     PubMed     Abstract available
     
     
     
128. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
     Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
     Eur J Haematol. 2021;107:489-496.
     PubMed     Abstract available
     
     
     September 2021
129. KRISTJANSDOTTIR ER, Toksvang LN, Schmiegelow K, Rank CU, et al
     Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival.
     Eur J Haematol. 2021 Sep 25. doi: 10.1111/ejh.13711.
     PubMed     Abstract available
     
     
     
130. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
     TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
     Eur J Haematol. 2021;107:364-369.
     PubMed     Abstract available
     
     
     
131. NOVITZKY-BASSO I, Chen C, Chen S, Lipton JH, et al
     Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR.
     Eur J Haematol. 2021;107:354-363.
     PubMed     Abstract available
     
     
     
132. NGAI LL, Ma CY, Maguire O, Do AD, et al
     Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
     Eur J Haematol. 2021;107:343-353.
     PubMed     Abstract available
     
     
     
133. CRYSANDT M, Soysal H, Jennes E, Holtick U, et al
     Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility.
     Eur J Haematol. 2021;107:324-332.
     PubMed     Abstract available
     
     
     
134. VERLINDEN A, Schroyens WA, Gadisseur AP
     Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
     Eur J Haematol. 2021;107:377-379.
     PubMed    
     
     
     
135. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
     Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
     Eur J Haematol. 2021;107:311-317.
     PubMed     Abstract available
     
     
     August 2021
136. RAUTENBERG C, Lauseker M, Kaivers J, Jager P, et al
     Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
     Eur J Haematol. 2021;107:283-292.
     PubMed     Abstract available
     
     
     July 2021
137. GRIFFIN JD, Song Y, Yang H, Freimark J, et al
     Posttransplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes.
     Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13692.
     PubMed     Abstract available
     
     
     
138. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
     Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
     Eur J Haematol. 2021;107:81-91.
     PubMed     Abstract available
     
     
     
139. BRAGA LEMOS M, Rodrigues SR, Schroeder T, Kulasekararaj AG, et al
     Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.
     Eur J Haematol. 2021;107:3-23.
     PubMed     Abstract available
     
     
     June 2021
140. PUNGOLINO E, D'adda M, De Canal G, Trojani A, et al
     Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: final report of the PhilosoPhi34 study.
     Eur J Haematol. 2021 Jun 17. doi: 10.1111/ejh.13680.
     PubMed     Abstract available
     
     
     
141. MORABITO F, Tripepi G, Vigna E, Bossio S, et al
     Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
     Eur J Haematol. 2021;106:831-835.
     PubMed     Abstract available
     
     
     May 2021
142. MACHHERNDL-SPANDL S, Jager E, Barna A, Gurbisz M, et al
     Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukemia.
     Eur J Haematol. 2021 May 16. doi: 10.1111/ejh.13647.
     PubMed     Abstract available
     
     
     
143. JONSDOTTIR G, Bjorkholm M, Turesson I, Hultcrantz M, et al
     Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
     Eur J Haematol. 2021 May 9. doi: 10.1111/ejh.13650.
     PubMed     Abstract available
     
     
     
144. JACOBSEN N, Frisch T, Keiding N, Heilmann C, et al
     High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.
     Eur J Haematol. 2021;106:643-653.
     PubMed     Abstract available
     
     
     
145. KLYUCHNIKOV E, Christopeit M, Badbaran A, Bacher U, et al
     Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML.
     Eur J Haematol. 2021;106:606-615.
     PubMed     Abstract available
     
     
     April 2021
146. TEY A, Shaw B, Cardamone L, Shepherd S, et al
     Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
     Eur J Haematol. 2021 Apr 7. doi: 10.1111/ejh.13631.
     PubMed     Abstract available
     
     
     
147. BARTELS S, Vogtmann J, Schipper E, Busche G, et al
     Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
     Eur J Haematol. 2021;106:520-528.
     PubMed     Abstract available
     
     
     February 2021
148. HAGGLUND H, Yavuz AS, Dreimane A, Malm C, et al
     Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.
     Eur J Haematol. 2021;106:290-293.
     PubMed     Abstract available
     
     
     January 2021
149. MONTORO J, Roldan E, Pinana JL, Barba P, et al
     Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
     Eur J Haematol. 2021;106:114-125.
     PubMed     Abstract available
     
     
     
150. GAMBACORTI-PASSERINI C, Chen C, Davis C, Sen GP, et al
     Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data.
     Eur J Haematol. 2021;106:82-89.
     PubMed     Abstract available
     
     
     November 2020
151. PICARDI M, Giordano C, Della Pepa R, Cerchione C, et al
     Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667-671."
     Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.